Drug Profile
Research programme: angiogenesis inhibitors - XOMA
Alternative Names: BPI-derived compounds research programme - XOMA; Research programme: BPI-derived compounds - XOMA; Research programme: heparin neutralisers - XOMA; Research programme: retinal disorders - XOMA; Retinal disorders research programme - XOMA; XMP 300Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator XOMA
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases; Inflammation; Retinal disorders
Most Recent Events
- 14 Jun 2006 No development reported - Preclinical for Retinal disorders in USA (unspecified route)
- 20 Oct 2003 The BPI-derived compounds research programme is available for licensing for Retinal Disorders (http://www.xoma.com)
- 20 Oct 2003 No development reported - Preclinical for Cancer metastases in USA (unspecified route)